Year All2024202320222021202020192018201720162015 Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference April 28, 2022 Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 March 10, 2022 Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 1, 2022 Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations February 23, 2022 Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy February 22, 2022 Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium February 17, 2022 Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022 February 9, 2022 Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen January 10, 2022 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors December 20, 2021 Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting December 13, 2021
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 March 10, 2022
Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations February 23, 2022
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium February 17, 2022
Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen January 10, 2022
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors December 20, 2021
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting December 13, 2021